Cinven Completes Final Realisation of Medpace
August 24, 2018
International private equity firm Cinven has completed the final sell down of its remaining shares in Nasdaq-listed Medpace, realising its investment from the Fifth Cinven Fund. Medpace, a Cincinnati-based global contract research organisation (CRO), expanded internationally and grew its workforce substantially under Cinven's ownership before its August 2016 IPO and subsequent sell downs, with the final sell down achieved at a significant premium to the IPO price.
- Buyers
- Various public market investors
- Targets
- Medpace
- Sellers
- Cinven, Fifth Cinven Fund
- Industry
- Healthcare Services
- Location
- Ohio, United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Cinven Acquires Majority Stake in Ufinet International
December 21, 2021
Telecommunications
International private equity firm Cinven's Seventh Fund will make a majority investment in Ufinet International for an enterprise value of approximately €2.5 billion. Enel, the incumbent minority co-shareholder, will re-invest a minority stake; the deal supports Ufinet's continued international expansion, network investment and buy-and-build growth across Latin America.
-
Cinven Sells Minority Stakes in SYNLAB; Labcorp and Elliott Become Minority Investors
October 30, 2024
Healthcare Services
Cinven has sold an indirect minority stake in SYNLAB to strategic investor Labcorp while funds advised by Elliott have agreed to sell their direct stake to Ephios Bidco (Cinven-controlled) and reinvest proceeds to become an indirect minority shareholder alongside Cinven, Labcorp and Qatar Holding. The transactions leave Cinven as majority shareholder of SYNLAB and create opportunities for collaboration (including bringing Labcorp specialty tests to Europe); the Elliott transaction remains subject to regulatory approvals and is expected to close in early 2025.
-
Cinven Acquires Majority Stake in BioAgilytix; Cobepa Reinvests
December 20, 2021
Healthcare Services
International private equity firm Cinven has agreed to acquire a majority stake in BioAgilytix through a recapitalization, with current investor Cobepa remaining a significant minority investor. GHO Capital has realised its investment and will exit; the transaction will provide funding to support BioAgilytix’s international expansion, capacity and capability investments, and buy-and-build strategy in large-molecule bioanalytical services. BioAgilytix is headquartered in Durham, North Carolina and employs about 870 staff across the United States, Europe and Australia.
-
Cinven Acquires Ufinet International
May 14, 2018
Telecommunications
Cinven’s Sixth Fund has agreed to acquire Ufinet International, the international operations of Spanish fibre network operator Ufinet Group, for an undisclosed sum. The investment establishes Ufinet International as a platform for buy-and-build consolidation and further international expansion across Latin America, supporting continued network investment and growth.
-
Renovus Capital Partners Recapitalizes ClinicalMind, LLC
November 25, 2019
Healthcare Services
Renovus Capital Partners has recapitalized ClinicalMind, LLC to support expansion of the medical communications agency and growth of its enGauge SaaS technology. The equity financing will fund expansion of ClinicalMind’s strategic and tactical agency services and its physician-engagement and medical affairs SaaS platform; Excel Partners advised the sell-side while DLA Piper and BrownRudnick served as legal counsel.
-
Cinven Makes Significant Investment in Drake Software
February 5, 2021
Software
International private equity firm Cinven has agreed to make a significant growth investment in Drake Software, a Franklin, North Carolina–based provider of professional tax preparation software. The capital will support Drake's technology platform renewal, product enhancement, and market expansion while Jamie Stiles remains CEO; financial terms were not disclosed and the deal is subject to customary antitrust approvals.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.